Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 163-167

  Nakamura, Takamitsu ^a   Obata, Jun ei ^a   Hirano, Mitsumasa ^a   Kitta, Yoshinobu ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Kawabata, Ken ichi ^a   Watanabe, Kazuhiro ^a   Watanabe, Yosuke ^a   Mishina, Hideto ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Coronary artery disease; Prognosis; Remnant lipoproteins

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REMNANT LIKE LIPOPROTEIN PARTICLE CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIET THERAPY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

AGED; APOLIPOPROTEINS B; CARDIOLOGY; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TRIGLYCERIDES;

EID: 80052273201     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.04.040     Document Type: Article

References (27)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001, 285:2486-2497.
2. Mudd J.O., Borlaug B.A., Johnston P.V., et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007, 50:1735-1741.
3. Miller M., Ginsberg H.N., Schaefer E.J. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008, 101:1003-1008.
4. Arsenault B.J., Rana J.S., Stroes E.S., et al. Beyond low-density lipoprotein cholesterol respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009, 55:35-41.
5. Ray K.K., Cannon C.P., Cairns R., Morrow D.A., Ridker P.M., Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009, 29:424-430.
6. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
7. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44:720-732.
8. Havel R.J. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol 2000, 11:615-620.
9. Jones P.H. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Am J Cardiol 2008, 102:41L-47L.
10. Ballantyne C.M., Raichlen J.S., Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (measuring effective reductions in cholesterol using rosuvastatin) trial. J Am Coll Cardiol 2008, 52:626-632.
11. Nestel P., Billington T., Tada N., Nugent P., Fidge N. Heterogeneity of very-low-density lipoprotein metabolism in hyperlipidemic subjects. Metabolism 1983, 32:810-817.
12. Nakajima K., Saito T., Tamura A., et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993, 223:53-71.
13. Kugiyama K., Doi H., Motoyama T., et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998, 97:2519-2526.
14. Fukushima H., Sugiyama S., Honda O., et al. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J Am Coll Cardiol 2004, 43:2219-2224.
15. Nakamura T., Obata J.E., Takano H., et al. High serum levels of remnant lipoproteins predict ischemic stroke in patients with metabolic syndrome and mild carotid atherosclerosis. Atherosclerosis 2009, 202:234-240.
16. Fukushima H., Kugiyama K., Sugiyama S., et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol 2001, 88:1370-1373.
17. Nakamura T., Takano H., Umetani K., et al. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005, 181:321-327.
18. Royston P., Sauerbrei W. Stability of multivariable fractional polynomial models with selection of variables and transformations: a bootstrap investigation. Stat Med 2003, 22:639-659.
19. Twickler T.B., Dallinga-Thie G.M., Cohn J.S., Chapman M.J. Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype. Circulation 2004, 109:1918-1925.
20. Scientific Statement AHA AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000, 102:2284-2299.
21. Hodis H.N., Mack W.J. Triglyceride-rich lipoproteins and progression of atherosclerosis. Eur Heart J 1998, 19(SUPPL. A):A40-A44.
22. Doi H., Kugiyama K., Oka H., et al. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000, 102:670-676.
23. Imke C., Rodriguez B.L., Grove J.S., et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu heart study. Arterioscler Thromb Vasc Biol 2005, 25:1718-1722.
24. McNamara J.R., Shah P.K., Nakajima K., et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001, 154:229-236.
25. de Graaf J., van der Vleuten G.M., ter Avest E., Dallinga-Thie G.M., Stalenhoef A.F. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab 2007, 92:1269-1275.
26. Sentí M., Pedro-Botet J., Nogués X., Rubiés-Prat J. Influence of intermediate-density lipoproteins on the accuracy of the Friedewald formula. Clin Chem 1991, 37:1394-1397.
27. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.